Think Rheumatoid Arthritis: Causes, Consequences, and Management

Chairpeople:

Josef Smolen,¹ Costantino Pitzalis²

Speakers:

Josef Smolen,¹ Costantino Pitzalis,² Simon Jones,³ Frank McKenna⁴

1. Medical University of Vienna and Hietzing Hospital, Vienna, Austria
2. Experimental Medicine and Rheumatology, Barts and the London School of Medicine and Dentistry, London, UK
3. Division of Infection and Immunity, The School of Medicine, Cardiff University, Cardiff, UK
4. University of Manchester, Manchester, UK

Disclosure:

Professor Smolen has received grant support and/or honoraria from Abbvie, AstraZeneca, BMS, Celgene, Celtrion, GSK, ILTOO, Janssen, Lilly, MSD, Novartis-Sandoz, Pfizer, Roche, Samsung, and UCB. He is a co-editor of Rheumatology textbook (Elsevier), and a contributor to UpToDate. Professor Pitzalis has received consultant fees from various pharmaceutical and biotech companies; he has received honoraria and/or research/development grants from Abbott, AstraZeneca, MedImmune, Janssen (Johnson & Johnson), Pfizer, Sanofi, Roche, Genentech, Chugai, and UCB. Professor Jones has received grants/research support from Roche, NovImmune, and Ferring; he has also received honoraria or consultation fees from Roche, Chugai, NovImmune, Regeneron/Sanofi, Janssen (Johnson & Johnson), Eleven Biotherapeutics, Genentech, and UCB. Professor Jones has also participated in a speakers’ bureau sponsored by Roche and Chugai. Dr McKenna has received honoraria or consultant fees from Janssen and Sandoz, and has participated in a speakers’ bureau sponsored by Janssen.

Acknowledgements:

Writing assistance was provided by Kabira Alieva of ApotheCom.

Support:

The symposium was sponsored by Janssen Pharmaceutica NV. Authors received honoraria for preparation and delivery of their presentations. The views and opinions expressed are those of the authors and not necessarily of Janssen Pharmaceutica NV.

Citation:

EMJ Rheumatol. 2016;3[1]:66-73. DOI/10.33590/emjrheumatol/10314552. https://doi.org/10.33590/emjrheumatol/10314552.

Keywords:

EULAR, European League Against Rheumatism

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.